miR-193b-3p和miR-346在面腹侧髓中产生抗高血压作用
Shuai Zhang1, Xueping Wang2, Tengteng Dai2
1International Cooperation Laboratory of Molecular Medicine, Academy of Chinese Medical Sciences Zhejiang Chinese Medical University Hangzhou Zhejiang China.
Journal of the American Heart Association
|June 27, 2024
概括
在脑干中新发现的microRNAs (miRNAs).
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 体腹侧髓 (RVLM) 过度活跃会增加交感外流,导致高血压.
- 微RNAs (miRNAs) 在调节RVLM神经刺激和血压 (BP) 中的作用在很大程度上是未知的.
研究的目的:
- 研究miRNAs在自发高血压大鼠 (SHRs) 的RVLM中的作用.
- 探索特定miRNAs在调节神经元刺激性和BP方面的潜力.
- 阐明潜在的分子机制,包括潜在的目标和途径.
主要方法:
- 在SHR中进行RNA测序以分析RVLM小RNA.
- 在体内和体外实验中评估miRNA调制对神经元活动和BP的影响.
- 确定miRNA点,并调查相关途径,包括亡.
主要成果:
- 在SHRs的RVLM中确定了637个miRNA,其中miR-193b-3p和miR-346.6的水平降低.
- 在RVLM中增加miR-193b-3p和miR-346的表达降低了神经元刺激性,交感外流和SHR中的BP.
- 抑制这些miRNAs增加了神经元刺激性和BP在正常压力大鼠.
- miR-193b-3p针对Cdc42关氨酸核酸交换因子 (Arhgef9),影响神经元亡;这种途径与BP调节有关.
结论:
- miR-193b-3p和miR-346是RVLM中的新型调节剂,可以抑制高血压的进展.
- 这种miR-193b-3p/Arhgef9/apoptosis通路为高血压的发展提供了潜在的机制.
- 针对这些miRNAs是一个有前途的治疗策略,用于预防高血压.
关键词:
在Arhgef9中,我们可以使用Arhgef9.灭症 (apoptosis) 是一种死亡的过程.这种高血压,高血压.miR‐193b‐3p 的时间.在 miR-3466 的情况下.面部腹侧侧脑髓 面部腹侧脑髓更多相关视频
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
01:25Antihypertensive Drugs: Direct Renin Inhibitors
557
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
557
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
700
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
700
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
606
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
606
01:17Antihypertensive Drugs: Action of β1 Blockers
416
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
416
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
430
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
430